VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Sunday, January 11, 2026

Stock Comparison

Morningstar, Inc. vs Novo Nordisk A/S

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Morningstar, Inc.

MORN · NASDAQ

Market cap (USD)
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorFinancials
Industry
CountryUS
Data as of2026-01-10
Moat score
67/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Morningstar, Inc.'s moat claims, evidence, and risks.

View MORN analysis

Novo Nordisk A/S

NOVOB · Nasdaq Copenhagen

Market cap (USD)$1.7T
Gross margin (TTM)82.1%
Operating margin (TTM)42%
Net margin (TTM)32.9%
SectorHealthcare
IndustryBiotechnology
CountryDK
Data as of2025-12-28
Moat score
85/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Novo Nordisk A/S's moat claims, evidence, and risks.

View NOVOB analysis

Comparison highlights

  • Moat score gap: Novo Nordisk A/S leads (85 / 100 vs 67 / 100 for Morningstar, Inc.).
  • Segment focus: Morningstar, Inc. has 7 segments (34.6% in Morningstar Data and Analytics); Novo Nordisk A/S has 3 segments (71.1% in Diabetes care).
  • Moat breadth: Morningstar, Inc. has 6 moat types across 3 domains; Novo Nordisk A/S has 5 across 3.

Primary market context

Morningstar, Inc.

Morningstar Data and Analytics

Market

Investment data, research, and analytics platforms

Geography

Global

Revenue share

34.6%

Novo Nordisk A/S

Diabetes care

Market

Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)

Geography

Global

Customer

Payers/providers and patients (via wholesalers/pharmacies/hospitals)

Role

Originator pharma (R&D, regulatory, manufacturing, commercialization)

Revenue share

71.1%

Side-by-side metrics

Morningstar, Inc.
Novo Nordisk A/S
Ticker / Exchange
MORN - NASDAQ
NOVOB - Nasdaq Copenhagen
Market cap (USD)
n/a
$1.7T
Gross margin (TTM)
n/a
82.1%
Operating margin (TTM)
n/a
42%
Net margin (TTM)
n/a
32.9%
Sector
Financials
Healthcare
Industry
n/a
Biotechnology
HQ country
US
DK
Primary segment
Morningstar Data and Analytics
Diabetes care
Market structure
Oligopoly
Oligopoly
Market share
n/a
33.7% (reported)
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
67 / 100
85 / 100
Moat domains
Demand, Network, Legal
Legal, Supply, Demand
Last update
2026-01-10
2025-12-28

Moat coverage

Shared moat types

Regulated Standards PipeIP Choke Point

Morningstar, Inc. strengths

Data Workflow LockinDe Facto StandardSuite BundlingTraining Org Change Costs

Novo Nordisk A/S strengths

Capacity MoatBrand TrustLearning Curve Yield

Segment mix

Morningstar, Inc. segments

Full profile >

Morningstar Data and Analytics

Oligopoly

34.6%

PitchBook

Oligopoly

27.2%

Morningstar Credit

Oligopoly

12.8%

Morningstar Wealth

Competitive

10.9%

Morningstar Retirement

Competitive

5.6%

Morningstar Sustainalytics

Oligopoly

5.2%

Morningstar Indexes

Oligopoly

3.7%

Novo Nordisk A/S segments

Full profile >

Diabetes care

Oligopoly

71.1%

Obesity care

Duopoly

22.4%

Rare disease

Oligopoly

6.4%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.